{"generic":"Isavuconazonium Sulfate","drugs":["Cresemba","Isavuconazonium Sulfate"],"mono":{"0":{"id":"931366-s-0","title":"Generic Names","mono":"Isavuconazonium Sulfate"},"1":{"id":"931366-s-1","title":"Dosing and Indications","sub":[{"id":"931366-s-1-4","title":"Adult Dosing","mono":"<ul><li>Obtain specimens for fungal culture and laboratory studies, including histopathology, prior to initiating therapy; base continued treatment on cultures and laboratory results once available. Evaluate liver function tests at treatment initiation and continue monitoring during treatment.<\/li><li>Bioequivalence between IV and oral formulations has been demonstrated; may switch between formulations without an additional loading dose.<\/li><li><b>Aspergillosis, Invasive:<\/b> Initial loading dose, 372 mg ORALLY (2 capsules) or via IV infusion every 8 hours for 6 doses (48 hours)<\/li><li><b>Aspergillosis, Invasive:<\/b> Maintenance, 372 mg ORALLY (2 capsules) or via IV infusion once daily, starting 12 to 24 hours after the last loading dose<\/li><li><b>Mucormycosis, Invasive:<\/b> Initial loading dose, 372 mg ORALLY (2 capsules) or via IV infusion every 8 hours for 6 doses (48 hours)<\/li><li><b>Mucormycosis, Invasive:<\/b> Maintenance, 372 mg ORALLY (2 capsules) or via IV infusion once daily, starting 12 to 24 hours after the last loading dose<\/li><\/ul>"},{"id":"931366-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy have not been established in pediatric patients."},{"id":"931366-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Renal impairment (mild, moderate, or severe, including ESRD):<\/b> No dosage adjustment required.<\/li><li><b>Hepatic impairment (mild or moderate, Child-Pugh class A and B):<\/b> No dosage adjustment required.<\/li><li><b>Hepatic impairment (severe, Child-Pugh class C):<\/b> Use only if benefits outweigh potential risks; monitoring recommended.<\/li><li><b>Elderly (65 years or older):<\/b> No dosage adjustment required.<\/li><\/ul>"},{"id":"931366-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Aspergillosis, Invasive<\/li><li>Mucormycosis, Invasive<\/li><\/ul>"}]},"3":{"id":"931366-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931366-s-3-9","title":"Contraindications","mono":"<ul><li>Concomitant use with CYP3A4 inhibitors such as ketoconazole or high-dose ritonavir; increased plasma concentrations of isavuconazole (active moiety of isavuconazonium sulfate)<\/li><li>Concomitant use with CYP3A4 inducers such as rifampin, carbamazepine, St. John's wart, or long acting barbiturates; decreased plasma concentrations of isavuconazole (active moiety of isavuconazonium sulfate)<\/li><li>Familial short QT syndrome<\/li><li>Hypersensitivity to isavuconazole (active moiety of isavuconazonium sulfate)<\/li><\/ul>"},{"id":"931366-s-3-10","title":"Precautions","mono":"<ul><li>Dermatologic:<\/li><li>-- Serious hypersensitivity and severe skin reactions, such as Stevens Johnson syndrome, have been reported with other azole antifungals; discontinue if severe cutaneous reaction develops<\/li><li>Hepatic:<\/li><li>-- Elevations in ALT, AST, alkaline phosphatase, and total bilirubin have been reported; evaluate at baseline and monitoring recommended<\/li><li>-- Hepatitis, cholestasis, hepatic failure, and death have been reported in patients with serious underlying medical disease (eg, hematologic malignancy); evaluate at baseline, monitoring recommended, and discontinue if suspected<\/li><li>Immunologic:<\/li><li>-- Serious hypersensitivity reactions, such as anaphylaxis, have been reported with other azole antifungals; use cautiously in patients with hypersensitivity to other azole antifungals<\/li><li>Reproductive:<\/li><li>--Pregnancy; risk of embryo-fetal toxicity<\/li><li>Other:<\/li><li>-- Hypotension, dyspnea, chills, dizziness, paraesthesia, hypoesthesia have been reported during IV administration; discontinue<\/li><\/ul>"},{"id":"931366-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"931366-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"931366-s-4","title":"Drug Interactions","sub":[{"id":"931366-s-4-13","title":"Contraindicated","mono":"<ul><li>Aprepitant (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Efavirenz (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Mephobarbital (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Oxcarbazepine (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Ritonavir (probable)<\/li><li>Saquinavir (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><\/ul>"},{"id":"931366-s-4-14","title":"Major","mono":"<ul><li>Atorvastatin (theoretical)<\/li><li>Cyclosporine (theoretical)<\/li><li>Digoxin (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Lopinavir (probable)<\/li><li>Midazolam (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Sirolimus (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><\/ul>"},{"id":"931366-s-4-15","title":"Moderate","mono":"<ul>Bupropion (probable)<\/ul>"}]},"5":{"id":"931366-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Peripheral edema (15.2%)<\/li><li><b>Endocrine metabolic:<\/b>Hypokalemia (19.1%)<\/li><li><b>Gastrointestinal:<\/b>Constipation (14%), Diarrhea (23.7%), Nausea (27.6%), Vomiting (25%)<\/li><li><b>Musculoskeletal:<\/b>Backache (10.1%)<\/li><li><b>Neurologic:<\/b>Headache (16.7%)<\/li><li><b>Respiratory:<\/b>Cough (12%), Dyspnea (17.1%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hepatic:<\/b>Cholestasis, Hepatitis (Up to 5%), Increased liver function test (17.1%), Liver failure (Up to 5%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction (Up to 5%)<\/li><li><b>Renal:<\/b>Renal failure (10.1%)<\/li><li><b>Respiratory:<\/b>Acute respiratory failure (7.4%)<\/li><li><b>Other:<\/b>Infusion reaction (6.2%)<\/li><\/ul>"},"6":{"id":"931366-s-6","title":"Drug Name Info","sub":{"0":{"id":"931366-s-6-17","title":"US Trade Names","mono":"Cresemba<br\/>"},"2":{"id":"931366-s-6-19","title":"Class","mono":"<ul><li>Antifungal<\/li><li>Triazole<\/li><\/ul>"},"3":{"id":"931366-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"931366-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"931366-s-7","title":"Mechanism Of Action","mono":"Isavuconazonium sulfate is the prodrug of the azole antifungal, isavuconazole. Isavuconazole weakens the fungal cell membrane structure and function by inhibiting lanosterol 14-alpha-demethylase which prevents the conversion to ergosterol, part of the fungal cell membrane. Mammalian cells are less sensitive to isavuconazole inhibition of demethylation <br\/>"},"8":{"id":"931366-s-8","title":"Pharmacokinetics","sub":[{"id":"931366-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Isavuconazole, Oral: 3 hours (372 mg\/day); 4 hours (1116 mg\/day)<\/li><li>Bioavailability, Isavuconazole, Oral: 98%<\/li><li>Effects of food, Isavuconazole: Minimal<\/li><\/ul>"},{"id":"931366-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding, Isavuconazole: Greater than 99%<\/li><li>Vd, Isavuconazole: 450 L<\/li><\/ul>"},{"id":"931366-s-8-25","title":"Metabolism","mono":"<ul><li>Blood: Predominant site<\/li><li>Isavuconazole (major): Active<\/li><li>Isavuconazole (active moiety), substrate of CYP3A4 (sensitive), CYP3A5, and UGT<\/li><li>Isavuconazole (active moiety), inhibitor of CYP3A4 (moderate), CYP2C8, CYP2C9, CYP2C19, CYP2D6, and P-gp-, BCRP-, and OCT2-transporters<\/li><li>Isavuconazole (active moiety), inducer of CYP3A4, CYP2B6, CYP2C8, CYP2C9<\/li><\/ul>"},{"id":"931366-s-8-26","title":"Excretion","mono":"<ul><li>Renal excretion: 45.5% unchanged; less than 2% changed<\/li><li>Fecal: 46.1% unchanged<\/li><li>Dialyzable, Isavuconazole: Not readily<\/li><li>Total body clearance, Isavuconazole: 2.6 L\/hr (Western subjects); 1.6 L\/hr (Chinese subjects); 40% reduced (mild hepatic impairment); 48% (moderate hepatic impairment)<\/li><\/ul>"},{"id":"931366-s-8-27","title":"Elimination Half Life","mono":"Isavuconazole, 130 hours <br\/>"}]},"9":{"id":"931366-s-9","title":"Administration","mono":"<ul><li><b>Intravenous<\/b><br\/><ul><li>Reconstitute with 5 mL of sterile water for injection; shake gently to dissolve completely.<\/li><li>Add reconstituted vial to 250-mL infusion bag (NS or D5W); may store reconstituted vial for up to 1 hour if refrigerated.<\/li><li>Apply a 0.2 to 1.2 micron in-line filter with an in-line filter reminder sticker to infusion bag.<\/li><li>Gently roll infusion bag to minimize particulates; some visible particulates may appear and will be removed by in-line filtration.<\/li><li>Avoid vigorous shaking or vibration of infusion bag; do not use a pneumatic transport system.<\/li><li>Administer via IV infusion over at least 1 hour.<\/li><li>Do not infuse with other medications or IV solutions.<\/li><li>Flush line with NS or D5W before and after infusion.<\/li><li>Complete infusion within 6 hours of dilution if kept at room temperature or within 24 hours if kept under refrigeration.<\/li><\/ul><\/li><li><b>Oral<\/b><br\/><ul><li>Do not crush, chew, dissolve, or open capsules; swallow whole.<\/li><li>May take with or without food<\/li><\/ul><\/li><\/ul>"},"10":{"id":"931366-s-10","title":"Monitoring","mono":"<ul><li>Resolution of fungal infection indicates efficacy<\/li><li>Liver-related laboratory tests; at the beginning of and during treatment; signs and symptoms of hepatic toxicity if abnormal liver-related laboratory tests are observed<\/li><li>Adverse reactions, in patients with severe hepatic impairment<\/li><\/ul>"},"11":{"id":"931366-s-11","title":"How Supplied","mono":"<b>Cresemba<\/b><br\/><ul><li>Intravenous Powder for Solution: 372 MG<\/li><li>Oral Capsule: 186 MG<\/li><\/ul>"},"13":{"id":"931366-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report symptoms of hepatitis, cholestasis, or hepatic failure.<\/li><li>Instruct patient to report symptoms of exfoliative cutaneous reactions or Stevens-Johnson syndrome.<\/li><li>Side effects may include nausea, vomiting, diarrhea, headache, constipation, dyspnea, cough, peripheral edema, and back pain.<\/li><li>Injection side effects may include infusion-related reactions.<\/li><\/ul>"}}}